ArticleCase reports in endocrinology2025
A Decade With Sheehan's Syndrome: A Case Report and Personal Experience.
Article in Case reports in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sheehan's syndrome (SS) is a rare endocrine disorder caused by ischemic necrosis of the anterior pituitary gland secondary to massive postpartum hemorrhage (PPH) and shock. It commonly leads to multiple hormonal deficiencies, such as adrenal insufficiency, hypothyroidism, and hypopituitarism. Affected individuals may present with signs and symptoms including weight gain or loss, cold intolerance, hair loss, menstrual irregularities, and hypotension. Diagnosis is often delayed due to its nonspecific presentation and overlap with conditions like postpartum depression and chronic fatigue syndrome. This case report highlights the clinical presentation, management challenges, and complications associated with the delayed diagnosis of SS. Case Presentation: A 35-year-old female was diagnosed with SS in 2016, at the age of 26, following severe PPH and hemorrhagic shock after a vaginal delivery in 2013. Initially, she experienced failure to lactate, followed by amenorrhea, frontal balding, weight loss, hypotension, chronic fatigue, mood swings, and polyuria. For several years, her symptoms were misattributed to postpartum depression, resulting in delayed diagnosis and treatment. A comprehensive endocrine evaluation revealed secondary adrenal insufficiency, central hypothyroidism, and hypogonadotropic hypogonadism, as evidenced by low levels of ACTH, cortisol, TSH, free T4, FSH, LH, and prolactin. Magnetic resonance imaging (MRI) confirmed partial empty sella, supporting the diagnosis of SS. She was started on lifelong hormone replacement therapy (HRT) consisting of hydrocortisone, levothyroxine, and estrogen. She remained highly sensitive to hormone doses, requiring frequent adjustments every other month. Despite modifications, she continued to experience persistent symptoms, including fatigue, hair loss, extreme mood swings, night sweats, and gastrointestinal symptoms such as abdominal discomfort, epigastric pain (worsened on an empty stomach), nausea, vomiting, bloating, and passage of blood in stool, likely related to long-term medication use. Pregnancy was later achieved through ovulation induction using human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG). She developed an adrenal crisis during pregnancy, which was managed through hydrocortisone dose modification. The immediate postpartum period was uneventful under treatment, but she required close endocrine follow-up for ongoing metabolic and reproductive concerns. Conclusion: This case highlights the typical clinical presentation of SS in a postpartum patient, including lactation failure, fatigue, and amenorrhea, which can facilitate early diagnosis of this serious and potentially life-threatening condition. Delayed diagnosis is often linked to prolonged morbidity, affecting both quality of life and fertility. Lifelong HRT, regular endocrinological monitoring, and individualized treatment plans are essential for managing endocrine dysfunction, osteoporosis risk, and cardiovascular complications. Awareness, early screening, and multidisciplinary collaboration among endocrinologists, obstetricians, and reproductive specialists are pivotal in improving long-term outcomes and reducing diagnostic delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.